<DOC>
	<DOC>NCT01932372</DOC>
	<brief_summary>The objective of this Surveillance is to verify the following subject matters concerning Tofacitinib (Xeljanz) under general practice. 1) Occurrence of adverse reactions, factors that may potentially affect safety and efficacy 2ï¼‰ Long-term safety (particularly, malignant tumors and serious infections) and efficacy Occurrences of malignant tumors and serious infections will be compared with a control group.</brief_summary>
	<brief_title>Tofacitinib (Xeljanz) Special Investigation for Rheumatoid Arthritis</brief_title>
	<detailed_description>All the patients whom an investigator prescribes the Xeljanz or Standard of Care for rheumatoid arthritis should be registered consecutively until the number of subjects reaches target number in order to extract patients enrolled into the investigation at random.</detailed_description>
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis, Rheumatoid</mesh_term>
	<mesh_term>Tofacitinib</mesh_term>
	<mesh_term>Antirheumatic Agents</mesh_term>
	<mesh_term>Etanercept</mesh_term>
	<criteria>All patients receiving Tofacitinib (Xeljanz)</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Rheumatoid Arthritis</keyword>
	<keyword>Good Post Marketing Study Practice</keyword>
	<keyword>Tofacitinib</keyword>
	<keyword>Xeljanz</keyword>
	<keyword>Regulatory Post Marketing Commitment Plan</keyword>
</DOC>